NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetics testing services and global oncology contract research services, is providing an update on its discussions with MolDX and on its commercial launch activities for RaDaRTM, its proprietary...
Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic diseases, announced that it has enrolled the first patient as part of a Phase 2 study evaluating the safety...
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine. The study is being conducted at...
Tenon Medical’s Catamaran(TM) SI Joint Fusion System Receives Institutional Review Board Approval for Two Strategic Post Market Studies
Tenon Medical, Inc. (NASDQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, announced Institutional Review Board (IRB) approval from WCG IRB for two separate Tenon-sponsored post market clinical studies of the...
Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device
Theranica Ltd., a prescribed digital therapeutics company developing advanced digitally connected neuromodulation devices for migraine and other pain conditions, announced it has teamed up with Point32Health, the parent organization of Harvard Pilgrim Health Care and...
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT™,...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com